Tanya Stoyanova*
Stoyanova lab develops new cancer early detection approaches and therapeutic strategies for late stage cancers. The current research areas of interest are: 1) Targeted cancer therapies. Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers, including discovery and testing new therapeutic targets and new small molecule inhibitors. 2) Antibody-based therapies for advanced prostate and other metastatic epithelial cancers. Stoyanova lab develops and tests antibody-based strategies as targeted cancer therapies. 3) Combination therapies for metastatic cancers. We are testing multiple experimental agents in combination with FDA-approved cancer therapies to enhance therapeutic responses. 4) Protein-based biomarkers for cancer early detection. We are interested in the discovery and development of new tissue, blood, and urine-based biomarkers for significant prostate cancer and other epithelial cancers. 5) Imaging modalities for cancer. The lab is interested in developing new positron emission tomography (PET) imaging modalities for epithelial cancers to improve cancer early detection and monitor treatment responses. The ultimate goals of the laboratory are to improve the early diagnosis and prognosis of clinically significant cancers and guide the development of novel and effective therapeutic strategies for metastatic cancers.
Websites:
Department of Molecular and Medical Pharmacology Profile
Tanya Stoyanova's Bibliography
Stoyanova Lab
Donate to Stoyanova Lab
Publications:
Guimarães CF, Liu S, Wang J, Purcell E, Ozedirne T, Ren T, Aslan M, Yin Q, Reis RL, Stoyanova T, Demirci U. Co-axial hydrogel spinning for facile biofabrication of prostate cancer-like 3D models. Biofabrication. 2024 02 20; 16(2). view on PubMed
Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Rep Med. 2024 Feb 20; 5(2):101381. view on PubMed
Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024 01 04; 14(1):486. view on PubMed
Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, Gunn D, Mao Z, Liu S, Yin Q, Riedinger M, Li K, Wu AM, Stoyanova T, Witte ON. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy. Proc Natl Acad Sci U S A. 2023 Nov 21; 120(47):e2312374120. view on PubMed
Shen M, Liu S, Toland A, Hsu EC, Hartono AB, Alabi BR, Aslan M, Nguyen HM, Sessions CJ, Nolley R, Shi C, Huang J, Brooks JD, Corey E, Stoyanova T. ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. Br J Cancer. 2023 11; 129(11):1818-1828. view on PubMed
Garcia-Marques FJ, Zakrasek E, Bermudez A, Polasko AL, Liu S, Stoyanova T, Brooks JD, Lavelle J, Pitteri SJ. Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients. Am J Clin Exp Urol. 2023; 11(3):206-219. view on PubMed
Wu WE, Chang E, Jin L, Liu S, Huang CH, Kamal R, Liang T, Aissaoui NM, Theruvath AJ, Pisani L, Moseley M, Stoyanova T, Paulmurugan R, Huang J, Mitchell DA, Daldrup-Link HE. Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models. Invest Radiol. 2023 06 01; 58(6):388-395. view on PubMed
Alabi BR, Liu S, Stoyanova T. Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther. 2022 10; 238:108255. view on PubMed
Wang J, Soto F, Liu S, Zeng Y, Hsu EC, Akin D, Sinclair B, Stoyanova T, Demirci U. . Volbots: Volvox Microalgae-Based Robots for Multimode Precision Imaging and Therapy. Advanced Functional Materials. 2022. view on PubMed
Wang J, Soto F, Ma P, Ahmed R, Yang H, Chen S, Wang J, Liu C, Akin D, Fu K, Cao X, Chen P, Hsu EC, Soh HT, Stoyanova T, Wu JC, Demirci U. Acoustic Fabrication of Living Cardiomyocyte-based Hybrid Biorobots. ACS Nano. 2022 07 26; 16(7):10219-10230. view on PubMed
Liu S, Alabi BR, Yin Q, Stoyanova T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022 11; 86(Pt 3):57-68. view on PubMed
Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 Dec; 63(12):1829-1835. view on PubMed
Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022 02 15; 3(2):100502. view on PubMed
Garcia-Marques F, Liu S, Totten SM, Bermudez A, Tanimoto C, Hsu EC, Nolley R, Hembree A, Stoyanova T, Brooks JD, Pitteri SJ. Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022 04; 82(5):605-616. view on PubMed
Liu S, Hsu EC, Shen M, Aslan M, Stoyanova T. Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. Methods Mol Biol. 2022; 2472:221-233. view on PubMed
Aslan M, Hsu EC, Garcia-Marques FJ, Bermudez A, Liu S, Shen M, West M, Zhang CA, Rice MA, Brooks JD, West R, Pitteri SJ, Gyorffy B, Stoyanova T. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer. 2021 Oct 28; 7(1):141. view on PubMed
Guimarães CF, Ahmed R, Mataji-Kojouri A, Soto F, Wang J, Liu S, Stoyanova T, Marques AP, Reis RL, Demirci U. Engineering Polysaccharide-Based Hydrogel Photonic Constructs: From Multiscale Detection to the Biofabrication of Living Optical Fibers. Adv Mater. 2021 Dec; 33(52):e2105361. view on PubMed
Aslan M, Hsu EC, Liu S, Stoyanova T. Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021; 6(1):bpab014. view on PubMed
Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep. 2021 06 25; 11(1):13305. view on PubMed
Fite BZ, Hinostroza V, States L, Hicks-Nelson A, Baratto L, Kallianos K, Codari M, Yu B, Jha P, Shams M, Stoyanova T, Chapelin FF, Liu A, Rashidi A, Soto F, Quintana Y, Davidzon GA, Marycz K, Gibbs IC, Chonde DB, Patel CB, Daldrup-Link HE. Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Mol Imaging Biol. 2021 10; 23(5):625-638. view on PubMed
Liu S, Garcia-Marques F, Zhang CA, Lee JJ, Nolley R, Shen M, Hsu EC, Aslan M, Koul K, Pitteri SJ, Brooks JD, Stoyanova T. Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Sci Rep. 2021 04 07; 11(1):7612. view on PubMed
Chen YS, Zhao Y, Beinat C, Zlitni A, Hsu EC, Chen DH, Achterberg F, Wang H, Stoyanova T, Dionne J, Gambhir SS. Ultra-high-frequency radio-frequency acoustic molecular imaging with saline nanodroplets in living subjects. Nat Nanotechnol. 2021 06; 16(6):717-724. view on PubMed
Xie J, Rice MA, Chen Z, Cheng Y, Hsu EC, Chen M, Song G, Cui L, Zhou K, Castillo JB, Zhang CA, Shen B, Chin FT, Kunder CA, Brooks JD, Stoyanova T, Rao J. In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification. Cancer Res. 2021 05 01; 81(9):2510-2521. view on PubMed
Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021; 9(1):73-87. view on PubMed
Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Res. 2021 03 15; 81(6):1583-1594. view on PubMed
Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ, Stoyanova T. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer. 2021 03; 124(5):896-900. view on PubMed
Buckup M, Rice MA, Hsu EC, Garcia-Marques F, Liu S, Aslan M, Bermudez A, Huang J, Pitteri SJ, Stoyanova T. Plectin is a regulator of prostate cancer growth and metastasis. Oncogene. 2021 01; 40(3):663-676. view on PubMed
Tailor D, Going CC, Resendez A, Kumar V, Nambiar DK, Li Y, Dheeraj A, LaGory EL, Ghoochani A, Birk AM, Stoyanova T, Ye J, Giaccia AJ, Le QT, Singh RP, Sledge GW, Pitteri SJ, Malhotra SV. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. Br J Cancer. 2021 02; 124(3):604-615. view on PubMed
Li D, Liu Q, Qi Q, Shi H, Hsu EC, Chen W, Yuan W, Wu Y, Lin S, Zeng Y, Xiao Z, Xu L, Zhang Y, Stoyanova T, Jia W, Cheng Z. Gold Nanoclusters for NIR-II Fluorescence Imaging of Bones. Small. 2020 10; 16(43):e2003851. view on PubMed
Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, Peehl DM, Zoubeidi A, Gambhir SS, Kunder CA, Pitteri SJ, Brooks JD, Stoyanova T. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020 01 28; 117(4):2032-2042. view on PubMed
Rice MA, Malhotra SV, Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 2019; 9:801. view on PubMed
Rice MA, Hsu EC, Aslan M, Ghoochani A, Su A, Stoyanova T. Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies. Mol Cancer Ther. 2019 07; 18(7):1230-1242. view on PubMed
Rice MA, Stoyanova T. . Biomarkers for Diagnosis and Prognosis of Prostate Cancer. Prostatectomy. 2018. view on PubMed
Going CC, Tailor D, Kumar V, Birk AM, Pandrala M, Rice MA, Stoyanova T, Malhotra S, Pitteri SJ. Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer. J Proteome Res. 2018 10 05; 17(10):3574-3585. view on PubMed
Liu F, Vermesh O, Mani V, Ge TJ, Madsen SJ, Sabour A, Hsu EC, Gowrishankar G, Kanada M, Jokerst JV, Sierra RG, Chang E, Lau K, Sridhar K, Bermudez A, Pitteri SJ, Stoyanova T, Sinclair R, Nair VS, Gambhir SS, Demirci U. The Exosome Total Isolation Chip. ACS Nano. 2017 11 28; 11(11):10712-10723. view on PubMed
Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep. 2016 12 06; 17(10):2596-2606. view on PubMed
Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):E6457-E6466. view on PubMed
Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG. v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res. 2016 11 15; 76(22):6723-6734. view on PubMed
Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11; 166(4):1041-1054. view on PubMed
Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11; 29(4):536-547. view on PubMed
Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2016 Feb; 76(2):125-39. view on PubMed
Stoyanova T, Goldstein AS. Distinct phases of human prostate cancer initiation and progression can be driven by different cell-types. Cancer Cell Microenviron. 2014; 1(3). view on PubMed
Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn DB, Huang J, Witte ON, Goldstein AS. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A. 2013 Dec 10; 110(50):20111-6. view on PubMed
Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013 Dec 03; 110(49):E4762-9. view on PubMed
Stoyanova TI, Goldstein AS. Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells. Asian J Androl. 2013 Jan; 15(1):83-4. view on PubMed
Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev. 2012 Oct 15; 26(20):2271-85. view on PubMed
Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4672-81. view on PubMed
Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, Graeber TG, Witte ON. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012 Jan 31; 109(5):1643-8. view on PubMed
Stoyanova T, Roy N, Bhattacharjee S, Kopanja D, Valli T, Bagchi S, Raychaudhuri P. p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies. J Biol Chem. 2012 Jan 27; 287(5):3019-28. view on PubMed
Kopanja D, Roy N, Stoyanova T, Hess RA, Bagchi S, Raychaudhuri P. Cul4A is essential for spermatogenesis and male fertility. Dev Biol. 2011 Apr 15; 352(2):278-87. view on PubMed
Goldstein AS, Stoyanova T, Witte ON. Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol. 2010 Oct; 4(5):385-96. view on PubMed
Stoyanova T, Roy N, Kopanja D, Raychaudhuri P, Bagchi S. DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response. Cell Cycle. 2009 Dec 15; 8(24):4067-71. view on PubMed
Stoyanova T, Roy N, Kopanja D, Bagchi S, Raychaudhuri P. DDB2 decides cell fate following DNA damage. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10690-5. view on PubMed
Kopanja D, Stoyanova T, Okur MN, Huang E, Bagchi S, Raychaudhuri P. Proliferation defects and genome instability in cells lacking Cul4A. Oncogene. 2009 Jul 02; 28(26):2456-65. view on PubMed
Stoyanova T, Yoon T, Kopanja D, Mokyr MB, Raychaudhuri P. The xeroderma pigmentosum group E gene product DDB2 activates nucleotide excision repair by regulating the level of p21Waf1/Cip1. Mol Cell Biol. 2008 Jan; 28(1):177-87. view on PubMed
